

### **Annex III**

#### **Conditions of the marketing authorisation**

National Competent Authorities, coordinated by the Reference Member State where applicable, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders:

A case-control study shall be performed to further investigate the possibility of an association between pholcodine use and NMBA-related anaphylactic reactions. A draft protocol should be submitted to CHMP for assessment and approval within 3 months of the Commission Decision. The final study report should be submitted to the National Competent Authorities by December 2016.